Provectus Biopharmaceuticals IncOTCQB:PVCT
- LAST PRICE0.1227
- TODAY'S CHANGE (%)-0.0072 (-5.5427%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1299 / 0.1299
- Day Range
- 52 Week Range
- Volume135,264
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PVCT |
|---|---|---|
| 09:32 ET | 1607 | 0.1299 |
| 10:30 ET | 1000 | 0.125 |
| 11:20 ET | 2500 | 0.12175 |
| 11:24 ET | 2500 | 0.12175 |
| 11:27 ET | 5000 | 0.1225 |
| 11:40 ET | 1000 | 0.1225 |
| 12:03 ET | 4000 | 0.12 |
| 12:43 ET | 5100 | 0.12 |
| 01:35 ET | 10000 | 0.1165 |
| 01:44 ET | 300 | 0.116585 |
| 01:51 ET | 5000 | 0.125 |
| 01:53 ET | 2500 | 0.12075 |
| 01:57 ET | 4900 | 0.12375 |
| 02:08 ET | 9000 | 0.12375 |
| 02:29 ET | 10000 | 0.1249 |
| 03:18 ET | 60803 | 0.125 |
| 03:38 ET | 10000 | 0.1227 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Provectus Biopharmaceuticals Inc | 54.5M | -15.4x | --- |
Praxis Precision Medicines Inc | 54.5M | -0.3x | --- |
Manuka Inc | 55.8M | -9.4x | --- |
Viracta Therapeutics Inc | 54.2M | -1.1x | --- |
Galecto Inc | 54.9M | -1.0x | --- |
Abeona Therapeutics Inc | 57.5M | -0.8x | --- |
Company Information
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing immunotherapy medicines for different diseases that are based on a class of synthetic small-molecule immuno-catalysts called halogenated xanthenes (HXs). The Company’s lead molecule is named rose bengal sodium (RBS). The Company’s small molecule HX medical science platform comprises a range of different drug product candidates and preclinical pharmaceutical-grade RBS formulations using different concentrations and delivered by different routes of administration specific to each disease area and/or indication. The Company’s HX medical science platform includes clinical development programs in oncology, dermatology, and ophthalmology; in vivo proof-of-concept drug discovery programs in oncology, hematology, wound healing, and animal health, and in vitro drug discovery programs in infectious diseases and tissue regeneration and repair.
Contact Information
- Headquarters
- 10025 Investment Drive, Suite 250KNOXVILLE, TN, United States 37932
- Phone
- 865-769-4011
- Fax
- 302-674-5266
Executives
- Independent Chairman of The Board
- Edward Pershing
- Non-Executive Independent Vice Chairman of the Board
- Dominic Rodrigues
- Chief Financial Officer
- Heather Raines
- Chief Operating Officer, Director
- Bruce Horowitz
- Chief Technology Officer
- Eric Wachter
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $54.5M |
|---|---|
Revenue (TTM) | $1.0M |
Shares Outstanding | 419.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.46 |
EPS | $-0.01 |
Book Value | $-0.01 |
P/E Ratio | -15.4x |
Price/Sales (TTM) | 54.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -318.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
